KMDA
Price
$7.14
Change
+$0.08 (+1.13%)
Updated
Sep 5 closing price
Capitalization
401.71M
67 days until earnings call
SGIOY
Price
$8.99
Change
+$0.26 (+2.98%)
Updated
Sep 5 closing price
Capitalization
15.32B
51 days until earnings call
Interact to see
Advertisement

KMDA vs SGIOY

Header iconKMDA vs SGIOY Comparison
Open Charts KMDA vs SGIOYBanner chart's image
Kamada
Price$7.14
Change+$0.08 (+1.13%)
Volume$129.8K
Capitalization401.71M
Shionogi & Co
Price$8.99
Change+$0.26 (+2.98%)
Volume$84.38K
Capitalization15.32B
KMDA vs SGIOY Comparison Chart in %
Loading...
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGIOY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KMDA vs. SGIOY commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KMDA is a StrongBuy and SGIOY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (KMDA: $7.14 vs. SGIOY: $8.99)
Brand notoriety: KMDA and SGIOY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KMDA: 252% vs. SGIOY: 108%
Market capitalization -- KMDA: $401.71M vs. SGIOY: $15.32B
KMDA [@Pharmaceuticals: Generic] is valued at $401.71M. SGIOY’s [@Pharmaceuticals: Generic] market capitalization is $15.32B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KMDA’s FA Score shows that 0 FA rating(s) are green whileSGIOY’s FA Score has 2 green FA rating(s).

  • KMDA’s FA Score: 0 green, 5 red.
  • SGIOY’s FA Score: 2 green, 3 red.
According to our system of comparison, SGIOY is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KMDA’s TA Score shows that 4 TA indicator(s) are bullish while SGIOY’s TA Score has 5 bullish TA indicator(s).

  • KMDA’s TA Score: 4 bullish, 4 bearish.
  • SGIOY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SGIOY is a better buy in the short-term than KMDA.

Price Growth

KMDA (@Pharmaceuticals: Generic) experienced а +3.18% price change this week, while SGIOY (@Pharmaceuticals: Generic) price change was +4.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

KMDA is expected to report earnings on Nov 12, 2025.

SGIOY is expected to report earnings on Oct 27, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SGIOY($15.3B) has a higher market cap than KMDA($402M). KMDA has higher P/E ratio than SGIOY: KMDA (22.31) vs SGIOY (13.29). SGIOY YTD gains are higher at: 29.169 vs. KMDA (20.601). SGIOY has higher annual earnings (EBITDA): 206B vs. KMDA (34.2M). SGIOY has more cash in the bank: 576B vs. KMDA (66M). KMDA has less debt than SGIOY: KMDA (11.4M) vs SGIOY (11.7B). SGIOY has higher revenues than KMDA: SGIOY (419B) vs KMDA (170M).
KMDASGIOYKMDA / SGIOY
Capitalization402M15.3B3%
EBITDA34.2M206B0%
Gain YTD20.60129.16971%
P/E Ratio22.3113.29168%
Revenue170M419B0%
Total Cash66M576B0%
Total Debt11.4M11.7B0%
FUNDAMENTALS RATINGS
KMDA vs SGIOY: Fundamental Ratings
KMDA
SGIOY
OUTLOOK RATING
1..100
677
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
22
Undervalued
PROFIT vs RISK RATING
1..100
10091
SMR RATING
1..100
782
PRICE GROWTH RATING
1..100
5152
P/E GROWTH RATING
1..100
3745
SEASONALITY SCORE
1..100
7565

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SGIOY's Valuation (22) in the null industry is somewhat better than the same rating for KMDA (71) in the Biotechnology industry. This means that SGIOY’s stock grew somewhat faster than KMDA’s over the last 12 months.

SGIOY's Profit vs Risk Rating (91) in the null industry is in the same range as KMDA (100) in the Biotechnology industry. This means that SGIOY’s stock grew similarly to KMDA’s over the last 12 months.

SGIOY's SMR Rating (2) in the null industry is significantly better than the same rating for KMDA (78) in the Biotechnology industry. This means that SGIOY’s stock grew significantly faster than KMDA’s over the last 12 months.

KMDA's Price Growth Rating (51) in the Biotechnology industry is in the same range as SGIOY (52) in the null industry. This means that KMDA’s stock grew similarly to SGIOY’s over the last 12 months.

KMDA's P/E Growth Rating (37) in the Biotechnology industry is in the same range as SGIOY (45) in the null industry. This means that KMDA’s stock grew similarly to SGIOY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KMDASGIOY
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
50%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
63%
Momentum
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
54%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
62%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 10 days ago
65%
Declines
ODDS (%)
Bearish Trend 9 days ago
66%
Bearish Trend 5 days ago
58%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
63%
Aroon
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
KMDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGIOY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MCHI61.351.05
+1.74%
iShares MSCI China ETF
STXI29.40N/A
N/A
Strive International Developed Mkts ETF
MART37.10-0.03
-0.08%
AllianzIM U.S. Large Cp Buffer10 Mar ETF
GSPY35.59-0.14
-0.38%
Gotham Enhanced 500 ETF
USDU26.30-0.11
-0.42%
WisdomTree Bloomberg US Dllr Bullish ETF

SGIOY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SGIOY has been loosely correlated with TAK. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if SGIOY jumps, then TAK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGIOY
1D Price
Change %
SGIOY100%
+2.98%
TAK - SGIOY
40%
Loosely correlated
+0.72%
ESAIY - SGIOY
36%
Loosely correlated
+2.66%
KMDA - SGIOY
27%
Poorly correlated
+1.13%
SCYX - SGIOY
23%
Poorly correlated
+2.43%
SUPN - SGIOY
22%
Poorly correlated
+1.25%
More